From Pixels to Biomarkers: How Quibim Is Redefining the Future of Precision Medicine

Download Frost & Sullivan’s Transformational Growth Leadership Interview with Angel Alberich-Bayarri, CEO of Quibim

From Imaging Algorithms to a Healthcare AI Leader

Angel Alberich-Bayarri, CEO of Quibim, in conversation with Anantharaman Viswanathan, Research Director, Frost & Sullivan

What began as a quest to make radiology more objective has today evolved into a mission to redefine diagnostics. In this exclusive Transformational Growth Leadership interview, Angel Alberich-Bayarri, CEO of Quibim, shares his journey from academic research in imaging biomarkers to building a global company at the forefront of AI-powered medical imaging.

“Images are digital biological samples — immortal and rich in information. Our mission is to transform them into biomarkers that improve diagnosis, treatment, and patient outcomes.”

— Angel Alberich-Bayarri, CEO, Quibim

Three Transformative Trends in AI-driven Imaging

Anantharaman Viswanathan: What major trends do you see shaping the future of imaging over the next five to ten years?

Angel Alberich-Bayarri: We are at the beginning of a transformation in how imaging is used across healthcare. Instead of being just a diagnostic snapshot, it will become a continuous, data-driven tool that empowers patients, informs treatments, and even prevents disease. I see three key trends driving this change:

1. Patient Empowerment & Data Access – Patients will increasingly own their imaging data and use AI-driven second opinions. Foundation models will interpret multiple modalities seamlessly.
2. Advanced Computing – Photonics-enabled chips and more powerful GPUs [graphics processing units] will accelerate processing, removing today’s memory bottlenecks.
3. Preventive Imaging & Whole-Body Scans – Imaging will move earlier in the patient journey, including presymptomatic screenings and systematic whole-body evaluations.

AI and Biopharma: A Symbiotic Future

Anantharaman Viswanathan: How does Quibim fit into the intersection of AI and biopharma?

Angel Alberich-Bayarri: Quibim is bridging AI-driven imaging with pharmaceutical innovation in three ways:

• Synthetic Control Arms: Imaging biomarkers can create virtual patient cohorts, accelerating ethical and cost-effective trials.
• Pre-approval Patient Stratification: AI models can predict treatment response and optimize trial recruitment.
• Post-approval Patient Identification: AI ensures consistent detection of eligible patients, reducing variability caused by radiologist subjectivity.

Quibim’s Five-year Growth Vision

Anantharaman Viswanathan: What’s your vision for Quibim in the next five years?

Angel Alberich-Bayarri: By 2030, Quibim aims to be the leading provider of imaging-based diagnostics for oncology and immunology, two areas driving most of biopharma’s top drugs. The strategy includes:

• Multi-year partnerships with the top 20 global biopharma companies
• Expansion across healthcare systems via strategic alliances with imaging device makers and software providers

Scaling regulatory clearances and global sales operations

Innovation, Differentiation, and Culture

Anantharaman Viswanathan: What differentiates Quibim from others in this space?

Angel Alberich-Bayarri: Quibim differentiates itself through:

• Ground Truth Data: Training AI not just on radiologist reads but also on pathology, achieving “superhuman” performance.
• Internal R&D: A robust in-house innovation engine ensures speed, agility, and IP ownership.
• Category Creation: Beyond products, Quibim is shaping a new category — turning imaging into an information business that generates knowledge, insights, and evidence for the medical community.

“We are not just building tools; we are building a new category of medicine based on imaging biomarkers.”
— Angel Alberich-Bayarri

Challenges and Industry Consolidation

Anantharaman Viswanathan: What challenges are you facing in scaling Quibim globally?

Angel Alberich-Bayarri: Quibim is navigating two key challenges:

• Scaling Globally: Competing with large incumbents while building independent sales channels.
• Data Access: Breaking silos by empowering patients to share imaging data for diagnostic innovation.

Looking ahead, Angel anticipates massive consolidation in the AI imaging space, with only a few dozen companies leading globally by 2030, echoing the dot-com evolution.

People, Feedback, and Continuous Improvement

Anantharaman Viswanathan: How do you ensure Quibim stays innovative and responsive to customers?

Angel Alberich-Bayarri: We invest heavily in:

• Customer Success: A proactive team helps hospitals and pharma partners unlock value from their imaging data.
• Post-market Surveillance: Continuous monitoring prevents model drift and ensures reliability.

Employee Empowerment: Internal innovation culture emphasizes ownership, experimentation, and resilience in the face of failures.

Final Message to the Industry

Anantharaman Viswanathan: What message would you like to leave with the healthcare and biopharma community?

Angel Alberich-Bayarri: Healthcare’s transformation depends on unlocking data. Patients hold the key. If we empower them to share imaging data, we can accelerate breakthroughs in diagnostics, drugs, and algorithms. The future of medicine is in their hands.